Clinical Trial Update: Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial of maintenance nimotuzumab for advanced esophageal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang University | Conditions: Stage IV Esophageal Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN